Current Oncology, Volume 22, Issue 11

Background: This systematic review addresses the question “What is the optimal targeted therapy for female patients with early-stage human epidermal growth factor receptor 2 (her2)–positive breast cancer?” Methods: The medline and embase databases we...

Breast tumours positive for HER2 (human epidermal growth factor receptor 2) represent approximately 20% of all breast cancer cases and are associated with an aggressive natural history. The advent of targeted anti-HER2 therapies has dramatically impr...

Despite advancements in the treatment of early-stage breast cancer, many patients still develop disease recurrence; others present with de novo metastatic disease. For most patients with advanced breast cancer, the primary treatment intent is noncura...

Background: Use of the neoadjuvant approach to treat breast cancer patients has increased since the early 2000s, but the overall pathway of care for such patients can be highly variable. The aim of our project was to establish a multidisciplinary con...

Questions: (1) In female patients with locally advanced breast cancer (labc) and good response to neoadjuvant chemotherapy (nact), including endocrine therapy, what is the role of breast-conserving surgery (bcs) compared with mastectomy? (2) In femal...

The Breast Cancer Disease Site Group of Cancer Care Ontario identified the need for new guidelines for the adjuvant systemic therapy of early-stage breast cancer. The specific question to be addressed was “What is the optimal adjuvant systemic therap...

I was delighted to be asked to act as guest editor of this Current Oncology supplement dedicated to breast cancer; it was the opportune time to publish the adjuvant breast cancer guidelines recently completed for Cancer Care Ontario’s Program in Evid...

Background: An increasing number of young women are delaying childbearing; hence, more are diagnosed with breast cancer (BCa) before having a family. No clear recommendations are currently available for counselling such a population on the safety of...

Background: The Program in Evidence-Based Care (pebc) of Cancer Care Ontario recently created an evidence-based consensus guideline on the systemic treatment of early breast cancer. The evidence for the guideline was compiled using a systematic revie...

Background: Cancer Care Ontario’s Program in Evidence-Based Care (pebc) recently created an evidence-based consensus guideline on the systemic treatment of early breast cancer. The evidence for the guideline was compiled using a systematic review to...